Related Experiment Video
Updated: Feb 27, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Approaches to obesity management
Arianne N Sweeting1,2, Ian D Caterson1,2
1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Internal Medicine Journal
|July 6, 2017
Summary
This review covers obesity management in Australia, detailing lifestyle interventions, pharmacotherapy, and bariatric surgery. It evaluates the safety and effectiveness of these diverse obesity treatments.
Area of Science:
- Medical Science
- Public Health
Background:
- Obesity is a complex chronic disease with significant public health implications.
- Effective management strategies are crucial for improving patient outcomes and reducing healthcare burdens.
Purpose of the Study:
- To provide a comprehensive overview of current obesity management approaches in Australia.
- To evaluate the safety and efficacy of various interventions, including lifestyle, pharmacotherapy, and bariatric surgery.
Main Methods:
- Systematic review of existing literature and clinical guidelines.
- Analysis of data on lifestyle interventions, pharmacological treatments, and surgical procedures.
- Assessment of safety profiles and efficacy metrics for each modality.
Main Results:
- Multiple lifestyle intervention strategies are available, with varying degrees of success.
- Pharmacotherapy options offer additional benefits for specific patient groups.
- Bariatric surgery demonstrates significant efficacy but requires careful patient selection and carries inherent risks.
Conclusions:
- A multi-faceted approach combining lifestyle changes, pharmacotherapy, and potentially bariatric surgery is optimal for obesity management.
- Individualized treatment plans are essential, considering patient-specific factors and preferences.
- Ongoing research is needed to refine existing therapies and develop novel interventions for obesity.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:24Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
01:21Drug Dosing: Obese Patients
315
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
315
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
322
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
249
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
249
01:26Atherosclerosis III: Management
512
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
512